Literature DB >> 24073247

Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study.

Ting-An Yen1, Hwai-I Yang, Wu-Shiun Hsieh, Hung-Chieh Chou, Chien-Yi Chen, Kuo-Inn Tsou, Po-Nien Tsao.   

Abstract

BACKGROUND: Preeclampsia remains a leading cause of maternal mortality and preterm delivery. Both preeclampsia and bronchopulmonary dysplasia (BPD) of prematurity are associated with impaired angiogenesis. However, the relationship between maternal preeclampsia and BPD remains controversial. This study aims to test whether or not preeclampsia is associated with development of BPD in a cohort of premature infants.
MATERIALS AND METHODS: We conducted a retrospective cohort study assessing the association between preeclampsia and the risk of developing BPD in very-low-birth-weight (VLBW) infants registered in the Premature Baby Foundation of Taiwan from 1997 through 2006. All 21 neonatal departments in Taiwan participated in the data collection. A total of 8,653 VLBW infants were registered in the database. The exclusion criteria included congenital anomalies, chromosome anomalies, infants that died before 36 weeks post-conceptual (PCA), and those whose BPD status were unavailable. BPD was defined as oxygen dependence at 36 weeks postmenstrual age. The association between maternal preeclampsia and BPD was assessed using a multivariate-adjusted logistic regression model.
RESULTS: In the end, a total of 5,753 cases were enrolled in this study. The incidence of preeclampsia was 14.7% (n=847) and the overall incidence of BPD was 34.9%. Infants with maternal preeclampsia had a higher gestational age, higher incidence of cesarean section and being small for their gestational age, lower incidence of respiratory distress syndrome, patent ductus arteriosus, and sepsis. BPD occurred significantly less frequently in the maternal preeclampsia group (24.1% vs. 36.7%; adjusted odds ratio: 0.78; 95% confidence interval, 0.62-0.98). Subgroup analysis showed that the association between preeclampsia and BPD was significant only in those VLBW infants with a gestational age between 31-34 weeks.
CONCLUSION: This data supports the association between fetal exposure to maternal preeclampsia and a reduced risk of BPD in relatively mature VLBW infants.

Entities:  

Mesh:

Year:  2013        PMID: 24073247      PMCID: PMC3779258          DOI: 10.1371/journal.pone.0075168

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Preeclampsia results in maternal and fetal morbidity and is a leading cause of preterm delivery [1,2]. The etiology of preeclampsia is not fully understood; however, recent evidence shows that an increase in circulating antiangiogenic factors plays an important role in its pathogenesis [3-6]. Impaired pulmonary vascular growth by altered signaling of angiogenic factors may play a role in the pathogenesis of bronchopulmonary dysplasia (BPD) [7]. Maternal antiangiogenic factors can cross the placenta and may affect angiogenic signaling, thereby altering the risk of BPD [8-13]. Several studies have analyzed the relationship between maternal preeclampsia and the risk of developing BPD in preterm infants [14-25]; however, the results possess a degree of variability and the issue remains controversial. In this report, we examine the association between preeclampsia and the risk of developing BPD in a large multicenter cohort of very-low-birth-weight (VLBW) infants alive at post-conceptual age (PCA) 36 weeks.

Materials and Methods

Study subjects

A total of 8,653 VLBW infants (birth weight less than 1501 g) were born and registered in the database of the Premature Baby Foundation of Taiwan between 1997 and 2006. All 21 neonatal departments in Taiwan participated in the data collection. The data collected included antenatal and perinatal history, infants’ delivery room and neonatal histories including diagnoses, complications during hospitalization, and clinical outcomes at discharge. Patient information received by the database coordinator was cross-checked with the national birth registry. The exclusion criteria included congenital anomalies, chromosome anomalies, infants that died before 36 weeks (PCA), and those whose BPD status were unavailable. Ninety-five infants with maternal chronic hypertension and 38 infants with maternal chronic hypertension with preeclampsia were also excluded. Preeclampsia was defined as a diastolic blood pressure of at least 90 mm Hg accompanied by proteinuria of at least 1+ (30 mg per deciliter) on dipstick testing or nondependent edema during pregnancy [26]. The gestational age (GA) was dated by the last menstrual period or the date of embryo transfer for in vitro fertilization.

Ethics Statement

The written informed consents were obtained from all their designated relatives. The study was approved by the Institutional Review Boards of each participating hospital, including National Taiwan University Hospital, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng Kung University Hospital, Tri-Service General Hospital, Chung Shan Medical University Hospital, Shin Kong Wu Ho-Su Memorial Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, and Joint Institutional Review Board for the other hospitals.

Outcome variables

Respiratory distress syndrome (RDS) was defined by clinical diagnosis and requiring surfactant therapy. Necrotizing enterocolitis (NEC) was defined using the criteria of Bell [27], and BPD was defined as oxygen dependence at 36 weeks PCA. We categorized infants as small for gestational age (SGA) if their birth weights were less than the 10th percentile for their gestational ages [28].

Statistical analysis

The chi-square test and Student’s t-test was used for comparing distributions of categorical variables and the continuous variables between groups, respectively. The multivariate logistic regression model was used to analyze the association between maternal preeclampsia and BPD risk adjusted for potential confounders. The confounders include demographic and clinical variables that were different between those with and without preeclampsia by univariate analysis. Adjusted odds ratios with a 95% confidence interval (CI) were derived to assess the magnitude of the association between various factors and BPD risk. Statistically significant levels were determined using the 2-tailed test (p<0.05). The association between preeclampsia and BPD was further examined in subgroup analysis with stratification according to GA, SGA, Cesarean section, sex, birth weight, singleton, RDS, patent ductus arteriosus (PDA), and Sepsis.

Results

A total of 5,753 VLBW infants, including 847 (14.7%) cases born to a mother with preeclampsia, were enrolled. The overall incidence of BPD was 34.9%. Infants born to a mother with preeclampsia were more likely to be of higher gestation, delivered via Cesarean section and being female, small for gestational age and of multiple births. They were also less likely to have RDS, NEC, PDA, and sepsis. The incidence of BPD was significantly lower in infants with maternal preeclampsia compared to those without maternal preeclampsia (24.1% vs. 36.7%; Table 1). The incidence of RDS was significantly lower in the preeclampsia group than in the control group (32% vs. 46%; Table 1; odds ratio (95% CI): 0.55 (0.47–0.64); Table 1). However, after adjusting for GA, BW, SGA, sex, and antenatal steroid usage, preeclampsia was found to have no effect on the incidence of RDS (odds ratio (95% CI): 1.07 (0.87-1.32); Table S1).
Table 1

Demographic and clinical variables in infants born to mothers with or without preeclampsia.

Parameter No preeclampsia Preeclampsia p-value
N=4906 N=847
Gestational age* 29 (27, 31)31 (29, 33)<0.001
Birth weight* 1200 (990, 1362)1198 (990, 1370)0.8657
Cesarean section No2155 (44.2)68 (8.1)<0.001
Yes2726 (55.9)777 (92.0)
Sex Female2348 (48.0)453 (53.7)0.002
Male2545 (52.0)390 (46.3)
SGA No3632 (74.0)226 (26.7)<0.001
Yes1274 (26.0)621 (73.3)
Singleton§ No1329 (27.2)124 (14.7)<0.001
Yes3561 (72.8)719 (85.3)
Antenatal steroid < 2 doses2902 (66.9)505 (67.0)0.9727
> 2 doses1435 (33.1)249 (33.0)
RDS** No2614 (54.0)564 (68.2)<0.0001
Yes2224 (46.0)263 (31.8)
NEC†† No4405 (90.0)780 (92.4)0.03
Yes487 (10.0)64 (7.6)
PDA‡‡ No3169 (64.9)631 (75.0)<0.001
Required treatment1717 (35.1)210 (25.0)
Sepsis§§ No3656 (74.9)667 (79.3)0.006
Yes1228 (25.1)174 (20.7)
Days on IPPV14.6 (26.3)7.3 (15.3)<0.001
Days on oxygen, CPAP, or IPPV41.9 (38.3)26.3 (29.3)<0.001
BPD1802 (36.7)204 (24.1)0.001
Duration of hospitalization73.8 (35.9)61.8 (27.6)<0.001

Abbreviations: SGA: small for gestational age; RDS: respiratory distress syndrome; NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; BPD: bronchopulmonary dysplasia; IPPV: intermittent positive pressure ventilation; CPAP: continuous positive pressure ventilation

* Data presented as median values (25th, 75th quartiles)

† A total of 27 subjects were missing for this variable

‡ A total of 17 subjects were missing for this variable

§ A total of 20 subjects were missing for this variable

‖ A total of 662 subjects were missing for this variable

** A total of 88 subjects were missing for this variable

† † A total of 17 subjects were missing for this variable

‡‡ A total of 26 subjects were missing for this variable

§§ A total of 28 subjects were missing for this variable

Abbreviations: SGA: small for gestational age; RDS: respiratory distress syndrome; NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; BPD: bronchopulmonary dysplasia; IPPV: intermittent positive pressure ventilation; CPAP: continuous positive pressure ventilation * Data presented as median values (25th, 75th quartiles) † A total of 27 subjects were missing for this variable ‡ A total of 17 subjects were missing for this variable § A total of 20 subjects were missing for this variable ‖ A total of 662 subjects were missing for this variable ** A total of 88 subjects were missing for this variable † † A total of 17 subjects were missing for this variable ‡‡ A total of 26 subjects were missing for this variable §§ A total of 28 subjects were missing for this variable In the multivariate logistic regression analysis which included preeclampsia, GA, Cesarean section, sex of baby, birth weight, SGA, singletons, RDS, PDA, and sepsis as risk predictors (Table 2), the preeclampsia was negatively associated with the risk of developing BPD, showing a multivariate-adjusted odds ratio (95% CI) of 0.78 (0.62-0.98). GA, male sex, birth weight, RDS, PDA, and sepsis were also associated with BPD risk. The corresponding odds ratio (95% CI) was 0.83 (0.78–0.88), 1.47 (1.28–1.68), 0.78 (0.74–0.82), 3.05 (2.65–3.52), 1.21 (1.05–1.39), and 1.43 (1.23–1.67), respectively (Table 2).
Table 2

Multivariate-adjusted odds ratio of developing BPD for various factors.

Parameter Odds ratio (95% CI) p-value
Preeclampsia (yes vs. no)0.78 (0.62,0.98)0.03
Gestational age0.83 (0.78,0.88)<.001
Cesarean section (yes vs. no)0.93 (0.80–1.08)0.31
Sex of baby (male vs. female)1.47 (1.28,1.68)<.001
Birth weight (per 100 grams)0.78 (0.74,0.82)<.001
SGA (yes vs. no)1.02 (0.79,1.30)0.90
Single (yes vs. no)1.13 (0.96,1.33)0.15
RDS (yes vs. no)3.05 (2.65,3.52)<.001
PDA (required treatment vs. no)1.21 (1.05,1.39)0.01
Sepsis (yes vs. no)1.43 (1.23–1.67)<.001

Abbreviations: SGA: small for gestational age; RDS: respiratory distress syndrome; PDA: patent ductus arteriosus

Abbreviations: SGA: small for gestational age; RDS: respiratory distress syndrome; PDA: patent ductus arteriosus Since GA and SGA are two known factors that are associated with the risk of BPD in preterm infants, we further performed the subgroup multivariate-adjusted analysis with stratification according to GA groups, SGA status, cearean section, sex, groups of body weight, singleton, RDS, and PDA. We observed a statistically significant association between preeclampsia and BPD in those VLBW infants with GA greater than 31 weeks (adjusted-OR, 0.51; 95% CI, 0.30–0.88), but not in other GA groups (Table 3). When we separated these VLBW infants into SGA and non-SGA groups, maternal preeclampsia decreased the risk of developing BPD only in SGA group (adjusted-OR, 0.64; 95% CI, 0.46–0.90) but not in non-SGA group (Table 4). We did not find a statistically significant association between maternal preeclampsia and BPD risk in all other subgroups (Figure 1).
Table 3

Multivariate-adjusted odds ratio of BPD for preeclampsia with stratification according to GA.

Preeclampsia GA: ≤27
GA: 27–29
GA: 29–31
GA: 31–34
n BPD n (%) n BPD n (%) n BPD n (%) N BPD n (%)
No1407955 (67.9)1455524 (36.0)1210249 (20.6)65871 (10.8)
Yes7552 (69.3)16278 (48.2)24855 (22.2)29918 (6.0)
OR (95% CI)[*] 0.96 (0.56–1.66)1.13 (0.78–1.63)0.98 (0.68–1.40)0.51 (0.30–0.88)
p-value0.8860.5100.8980.016

Abbreviations: GA: gestational age; BPD: bronchopulmonary dysplasia; OR: odds ratio; CI: confidence interval

OR is adjusted for sex, GA, RDS and SGA.

Table 4

Multivariate-adjusted logistic regression analysis of BPD development with stratification according to SGA.

Parameter SGA
Non-SGA
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Preeclampsia (yes vs. no)0.64 (0.46,0.90)0.010.85 (0.59,1.23)0.387
Gestational age0.70 (0.63,0.77)<.00010.58 (0.53,0.64)<.001
Birth weight (per 100 grams)0.70 (0.64,0.77)<.00010.76 (0.70,0.82)<.001
Cesarean section (yes vs. no)0.65 (0.44,0.95)0.02531.01 (0.84,1.21)0.944
Sex (male vs. female)1.61 (1.19,2.19)0.00221.32 (1.10,1.58)0.002
Single (yes vs. no)1.00 (0.71,1.40)0.99441.16 (0.94,1.44)0.1645
RDS (yes vs. no)4.38 (3.16,6.06)<.00013.07 (2.57,3.66)<.001
Patent ductus arteriosus (yes vs. no)2.15 (1.52,3.05)<.00011.17 (0.97,1.41)0.092
Sepsis (yes vs. no)1.36 (0.95,1.94)0.09241.36 (1.10,1.67)0.004

Abbreviations: SGA: small for gestational age; CI: confidence interval; RDS: respiratory distress syndrome

Figure 1

Subgroup analyses for the association between preeclampsia and BPD.

Odds ratios were adjusted for sex, GA (asa continuous variable), RDS, and SGA, except for the stratifying variables.

Abbreviations: GA: gestational age; BPD: bronchopulmonary dysplasia; OR: odds ratio; CI: confidence interval OR is adjusted for sex, GA, RDS and SGA. Abbreviations: SGA: small for gestational age; CI: confidence interval; RDS: respiratory distress syndrome

Subgroup analyses for the association between preeclampsia and BPD.

Odds ratios were adjusted for sex, GA (asa continuous variable), RDS, and SGA, except for the stratifying variables. When we focused on those extremely preterm infants with a gestational age <28 weeks or birth weight <1000 gm, we found that 11.8% (227/1924) of the infants fell into the preeclampsia group; the incidence of BPD was similar in preeclampsia and control group (56% (127/227) vs. 64% (1083/1697); OR (95% CI): 0.96 (0.67–1.39)). This data indicates that there is no association between preeclampsia and BPD in extremely preterm or extremely-low-birth-weight infants who are at higher risk of developing BPD.

Discussion

In this population-based large cohort study of VLBW infants, we found in overall Taiwanese infants, maternal preeclampsia to be an independent factor associated with a decreased risk of BPD (Table 2). However, this negative association was only valid in subgroup of VLBW infants with GA greater than 31 weeks and in SGA subgroup. We did not observe a statistically significant association in extremely preterm infants with GA < 28 weeks or birth weight < 1000 gm. RDS is one of the most common diseases in preterm infants and is also a leading cause of subsequent BPD [29]. The relationship between preeclampsia and RDS is controversial [30-36]. The discrepancy among these studies may in part be result from relatively small sample sizes. Recently, Langenveld et al. demonstrated that the incidence of RDS was reduced in late preterm infants born to mothers with preeclampsia [37]. In our study, we also found that VLBW infants with maternal preeclampsia were less likely to develop RDS than those without maternal preeclampsia (Table 1). However, this protective effect disappeared after adjustment for confounding variables (Table 1). RDS usually appeared in VLBW infants but not in late preterm neonates. The diagnosis of RDS is mainly based on chest radiography as Langenveld et al. did, thus the incidence in different reports may vary. To minimize the bias of diagnosis of RDS, we defined the RDS as VLBW infants with RDS who required surfactant therapy. Our data suggest that preeclampsia may not be associated with the risk of RDS in VLBW infants when GA, BW, SGA, sex, and antenatal steroid usage were taken into consideration. Previously, Hansen et al. and Korhonen et al. reported that maternal preeclampsia was an independent risk factor for BPD in multivariate analysis (odds ratio (95% CI): 18.7% (2.44–144.76) and 6.75% (1.22–37.3), respectively) [17,19]. Kurkinen-Räty et al. and Withagen et al. had similar findings as well [20,24]. However, Schlapbach et al., Cheng et al., Cetinkaya et al. and O’Shea et al. did not find this association [15,16,21,23]. In addition, Redline et al. studied the placenta and perinatal risk factors for BPD in VLBW infants [22]. Although no relationship between clinical preeclampsia and BPD was observed, placental acute atherosis (a placental indicator of preeclampsia) was found to be inversely related to BPD (7% vs. 12%; odds ratio, 0.2; 95% CI, 0.1–0.8). Recently, Hansen et al. demonstrated that BPD increased in infants exposed to preeclampsia and hypothesized that this may due to the maternal antiangiogenic state. However, their sample size is small. In this large multicenter study, we provided the evidence that maternal preeclampsia was associated with a decreased risk of BPD in overall VLBW infants. Nonetheless, with the large sample size, we were able to examine this association in depth and demonstrated that this protective effect was only seen in particular subgroups. In agreement with the report from O’Shea et al. [21], we found that preeclampsia does not affect the risk of BPD in extremely preterm or ELBW infants. In addition, we found that GA is a consistent independent risk factor of BPD in all our analyses, as was expected. This indicates that prematurity itself has a very important independent influence on developing BPD and this effect is not affected by preeclampsia (Table 3). Interestingly, when we performed subgroup analysis, the protective effect of maternal preeclampsia was found to be significant in a relatively mature group (GA: 31–34 weeks), especially for those without RDS. Our data showed that RDS and prematurity as indicated by the GA were both significantly and independently associated with BPD (Table 2). The extreme prematurity and RDS may have a very profound effect on the development of BPD to some extent that they mask the potential protective effect of preeclampsia. Conversely, the effect of preeclampsia was much more evident in a more mature preterm infant (31–34 weeks gestation), as shown in our study. Intrauterine growth restriction or SGA has been reported to be associated with both preeclampsia and BPD [12-14,16,38-44]. The protective effect of preeclampsia was only found in SGA, but not non-SGA, preterm infants in our report. The reason for this difference is unclear. One possible explanation is that the severity of preeclampsia is usually strongly negatively associated with fetus body weight. This may explain why the protective effect of preeclampsia was absent in the non-SGA group. The mechanism of preeclampsia that protects VLBW infants from BPD is not clear. Increasing circulating soluble Flt-1, a soluble form of vascular endothelial growth factor (VEGF) receptor-1 which can bind both VEGF and placenta growth factor (PGF), resulting impairment of angiogenic state was thought to be responsible for the pathogenesis of preeclampsia [3-6,45-47]. In developing lungs, disruption of VEGF signaling impaired angiogenesis decreased alveloarization [8,10,48]. Although the cord blood levels of sFlt-1 was also elevated in preeclampsia group [9,12], but the levels were significantly lower than maternal levels [9]. This resulted in only mild or no significant difference in VEGF levels between preeclampsia and control groups can be found [9,12]. Similarly, cord PGF levels were also lower in preterm infants born to mothers with preeclampsia [12]. In contrast to VEGF, elevated PGF expression contributed pulmonary emphysema in mouse model and increased risk of developing BPD in preterm infants [11,13]. Therefore, preeclampsia-decreased PGF levels in cord blood may possibly contribute to the protective effect vis-à-vis developing BPD in preterm infants [49]. The strength of our study was that it was a large multicenter cohort study, allowed us to assess the association between maternal preeclampsia and BPD in several subgroup analyses. Our study also had some limitations. First, the reliability of our data depended on the preciseness of pediatricians and case managers. Second, some data of interest were unavailable in some cases. However, the large size of this database and nondifferential misclassification minimized these influences. Third, the strategies of respiratory care differed among different hospitals. This indeed influences the overall incidence of BPD, but may not lead to bias because the strategy should be the same regardless of whether preterm infants were born to mothers with or without preeclampsia in the same hospital. Fourth, our cohort was defined by birth weight. However, because this could have caused overrepresentation of growth-retarded infants, we performed several subgroup analyses to avoid this problem. Finally, the definition of BPD used here is a traditional clinical definition but not a physiological definition, a discrepancy which reduced the overall rate of BPD and reduced the variation among centers [50]. However, this cohort started as early as 1997 when there were no criteria for physiological definition of BPD. In conclusion, our data supports the association between fetal exposure to maternal preeclampsia and a reduced risk of BPD in the particular subgroup of VLBW infants with gestational age greater than 31 weeks. The regression analyses on factors associated with RDS. (DOC) Click here for additional data file.
  50 in total

1.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

Authors:  Ravi Thadhani; Walter P Mutter; Myles Wolf; Richard J Levine; Robert N Taylor; Vikas P Sukhatme; Jeffrey Ecker; S Ananth Karumanchi
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Preterm delivery for maternal or fetal indications: maternal morbidity, neonatal outcome and late sequelae in infants.

Authors:  M Kurkinen-Räty; M Koivisto; P Jouppila
Journal:  BJOG       Date:  2000-05       Impact factor: 6.531

3.  Neonatal outcome of temporizing treatment in early-onset preeclampsia.

Authors:  M I Withagen; W Visser; H C Wallenburg
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-02       Impact factor: 2.435

4.  Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry.

Authors:  Josje Langenveld; Anita C J Ravelli; Anton H van Kaam; David P van der Ham; Maria G van Pampus; Martina Porath; Ben Willem Mol; Wessel Ganzevoort
Journal:  Am J Obstet Gynecol       Date:  2011-07-20       Impact factor: 8.661

5.  Chronic lung disease of prematurity and intrauterine growth retardation: a population-based study.

Authors:  Mithilesh K Lal; Bradley N Manktelow; Elizabeth S Draper; David J Field
Journal:  Pediatrics       Date:  2003-03       Impact factor: 7.124

6.  Do survival and morbidity of very-low-birth-weight infants vary according to the primary pregnancy complication that results in preterm delivery?

Authors:  E J Wolf; A M Vintzileos; T S Rosenkrantz; J F Rodis; C M Salafia; J G Pezzullo
Journal:  Am J Obstet Gynecol       Date:  1993-11       Impact factor: 8.661

7.  Placenta growth factor elevation in the cord blood of premature neonates predicts poor pulmonary outcome.

Authors:  Po-Nien Tsao; Shu-Chen Wei; Yi-Ning Su; Chien-Nan Lee; Hung-Chieh Chou; Wu-Shiun Hsieh; Fon-Jou Hsieh
Journal:  Pediatrics       Date:  2004-05       Impact factor: 7.124

8.  Early-onset preeclampsia and neonatal outcomes.

Authors:  Angie C Jelin; Yvonne W Cheng; Brian L Shaffer; Anjali J Kaimal; Sarah E Little; Aaron B Caughey
Journal:  J Matern Fetal Neonatal Med       Date:  2010-05

9.  Increased incidence of respiratory distress syndrome in infants following pregnancies complicated by hypertension.

Authors:  J R Bowen; G I Leslie; J D Arnold; M P Jones; E D Gallery
Journal:  Aust N Z J Obstet Gynaecol       Date:  1988-05       Impact factor: 2.100

10.  Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort.

Authors:  Jennifer Zeitlin; Mayass El Ayoubi; Pierre-Henri Jarreau; Elizabeth S Draper; Béatrice Blondel; Wolfgang Künzel; Marina Cuttini; Monique Kaminski; Ludwig Gortner; Patrick Van Reempts; Louis Kollée; Emile Papiernik
Journal:  J Pediatr       Date:  2010-06-17       Impact factor: 4.406

View more
  19 in total

1.  Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study.

Authors:  Héloïse Torchin; Pierre-Yves Ancel; François Goffinet; Jean-Michel Hascoët; Patrick Truffert; Diep Tran; Cécile Lebeaux; Pierre-Henri Jarreau
Journal:  Pediatrics       Date:  2016-02-18       Impact factor: 7.124

2.  Pregnancy-induced hypertension and neonatal outcomes: a systematic review and meta-analysis.

Authors:  A Razak; A Florendo-Chin; L Banfield; M G Abdul Wahab; S McDonald; P S Shah; A Mukerji
Journal:  J Perinatol       Date:  2017-11-02       Impact factor: 2.521

Review 3.  Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology.

Authors:  Renjithkumar Kalikkot Thekkeveedu; Milenka Cuevas Guaman; Binoy Shivanna
Journal:  Respir Med       Date:  2017-10-24       Impact factor: 3.415

Review 4.  Bronchopulmonary dysplasia: Pathogenesis and treatment.

Authors:  Asfia Banu Pasha; Xiao-Qing Chen; Guo-Ping Zhou
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

5.  Inflammatory and oxidative stress airway markers in premature newborns of hypertensive mothers.

Authors:  R J Madoglio; L M S S Rugolo; C S Kurokawa; M P A Sá; J C Lyra; L C O Antunes
Journal:  Braz J Med Biol Res       Date:  2016-08-01       Impact factor: 2.590

6.  Maternal age and long-term neurodevelopmental outcomes of preterm infants < 29 weeks gestational age.

Authors:  Julia DiLabio; Jill G Zwicker; Rebecca Sherlock; Sibasis Daspal; Prakesh S Shah; Vibhuti Shah
Journal:  J Perinatol       Date:  2020-07-21       Impact factor: 3.225

Review 7.  Postnatal Infections and Immunology Affecting Chronic Lung Disease of Prematurity.

Authors:  Gloria S Pryhuber
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

8.  Preeclampsia and Retinopathy of Prematurity in Very-Low-Birth-Weight Infants: A Population-Based Study.

Authors:  Hsin-Chung Huang; Hwai-I Yang; Hung-Chieh Chou; Chien-Yi Chen; Wu-Shiun Hsieh; Kuo-Inn Tsou; Po-Nien Tsao
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

9.  Fetal Doppler velocimetry and bronchopulmonary dysplasia risk among growth-restricted preterm infants: an observational study.

Authors:  Alessandra Lio; Paolo Rosati; Roberta Pastorino; Francesco Cota; Milena Tana; Chiara Tirone; Claudia Aurilia; Cinzia Ricci; Alessandro Gambacorta; Angela Paladini; Ilenia Mappa; Silvia Buongiorno; Gian Franco Zannoni; Costantino Romagnoli; Giovanni Vento
Journal:  BMJ Open       Date:  2017-07-20       Impact factor: 2.692

10.  Fresh versus frozen embryo transfer for full-term singleton birth: a retrospective cohort study.

Authors:  Junwei Zhang; Mingze Du; Zhe Li; Lulu Wang; Jijun Hu; Bei Zhao; Yingying Feng; Xiaolin Chen; Lijun Sun
Journal:  J Ovarian Res       Date:  2018-07-16       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.